Background and Aims
Methods
Results
Conclusions
Graphical abstract
Abbreviations:
AUC (area under the receiver-operating characteristic curve), EoE (eosinophilic esophagitis), EREFS (Eosinophilic Esophagitis Endoscopic Reference Score), ICC (intraclass correlation coefficient), RAM (Research and Development University of California Los Angeles appropriateness methodology), RCT (randomized controlled trial), SD (standard deviation), SES (standardized effect size), VAS (visual analog scale)Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Gastrointestinal EndoscopyReferences
- Pharmacotherapies for the treatment of eosinophilic esophagitis: state of the art review.Drugs. 2019; 79: 1419-1434
- Developing pharmacologic treatments for eosinophilic esophagitis: draft guidance from the United States Food and Drug Administration.Gastroenterology. 2019; 157: 275-277
- Development of a core outcome set for therapeutic studies in eosinophilic esophagitis (COREOS).J Allergy Clin Immunol. 2022; 149: 659-670
- The prevalence and diagnostic utility of endoscopic features of eosinophilic esophagitis: a meta-analysis.Clin Gastroenterol Hepatol. 2012; 10: 988-996
- Endoscopic assessment of the oesophageal features of eosinophilic oesophagitis: validation of a novel classification and grading system.Gut. 2013; 62: 489-495
- Heterogeneity in clinical, endoscopic, and histologic outcome measures and placebo response rates in clinical trials of eosinophilic esophagitis: a systematic review.Clin Gastroenterol Hepatol. 2018; 16: 1714-1729
- Accuracy of the eosinophilic esophagitis endoscopic reference score in diagnosis and determining response to treatment.Clin Gastroenterol Hepatol. 2016; 14: 31-39
- Variation in endoscopic activity assessment and endoscopy score validation in adults with eosinophilic esophagitis.Clin Gastroenterol Hepatol. 2019; 17: 1477-1488
- The RAND/UCLA appropriateness method user’s manual.RAND Corporation, Santa Monica, CA2001
- Systematic review: disease activity indices in eosinophilic esophagitis.Am J Gastroenterol. 2017; 112: 1658-1669
- Center for Drug Evaluation and Research: clinical outcome assessment (COA) compendium.2021 (Available at: https://www.fda.gov/drugs/development-resources/clinical-outcome-assessment-compendium. Accessed February 27, 2021)
- The measurement of observer agreement for categorical data.Biometrics. 1977; 33: 159-174
- The equivalence of weighted kappa and the intraclass correlation coefficient as measures of reliability.Educ Psychol Measure. 1973; 33: 613-619
- Generalizability of behavioral observations: a clarification of interobserver agreement and interobserver reliability.Am J Ment Defic. 1979; 83: 460-472
- Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation.Med Care. 2003; 41: 582-592
- Development and validation of the Nancy histological index for UC.Gut. 2017; 66: 43-49
- Development and validation of a histological index for UC.Gut. 2017; 66: 50-58
- Development and validation of a magnetic resonance index for assessing fistulas in patients with Crohn's disease.Gastroenterology. 2019; 157: 1233-1244
- Reliability of measuring ileo-colonic disease activity in Crohn's disease by magnetic resonance enterography.Inflamm Bowel Dis. 2018; 24: 440-449
- A power primer.Psychol Bull. 1992; 112: 155-159
- Symptoms have modest accuracy in detecting endoscopic and histologic remission in adults with eosinophilic esophagitis.Gastroenterology. 2016; 150: 581-590
- Development of a Core Outcome Set for Therapeutic Studies in Eosinophilic Esophagitis (COREOS): an international multidisciplinary consensus.Gastroenterology. 2021; 161: 748-755
- Sample size formulas for estimating intraclass correlation coefficients with precision and assurance.Stat Med. 2012; 31: 3972-3981
- Ankylosaurus back sign: novel endoscopic finding in esophageal eosinophilia patients indicating proton pump inhibitor response.Endosc Int Open. 2018; 6: E165-E172
- Evaluating the endoscopic reference score for eosinophilic esophagitis: moderate to substantial intra- and interobserver reliability.Endoscopy. 2014; 46: 1049-1055
- Reliability among central readers in the evaluation of endoscopic findings from patients with Crohn's disease.Gut. 2016; 65: 1119-1125
- Esophageal diameter is decreased in some patients with eosinophilic esophagitis and might increase with topical corticosteroid therapy.Clin Gastroenterol Hepatol. 2012; 10: 481-486
- Biomechanics of esophageal function in eosinophilic esophagitis.J Neurogastroenterol Motil. 2012; 18: 357-364
- Development and validation of a symptom-based activity index for adults with eosinophilic esophagitis.Gastroenterology. 2014; 147: 1255-1266
- Delay in diagnosis of eosinophilic esophagitis increases risk for stricture formation in a time-dependent manner.Gastroenterology. 2013; 145: 1230-1236
- Eosinophilic esophagitis reference score accurately identifies disease activity and treatment effects in children.Clin Gastroenterol Hepatol. 2018; 16: 1056-1063
- Budesonide oral suspension improves symptomatic, endoscopic, and histologic parameters compared with placebo in patients with eosinophilic esophagitis.Gastroenterology. 2017; 152: 776-786
- RPC4046, a monoclonal antibody against IL13, reduces histologic and endoscopic activity in patients with eosinophilic esophagitis.Gastroenterology. 2019; 156: 592-603
- Efficacy of dupilumab in a phase 2 randomized trial of adults with active eosinophilic esophagitis.Gastroenterology. 2020; 158: 111-122
- Efficacy of budesonide orodispersible tablets as induction therapy for eosinophilic esophagitis in a randomized placebo-controlled trial.Gastroenterology. 2019; 157: 74-86
- Antifibrotic effects of the thiazolidinediones in eosinophilic esophagitis pathologic remodeling: a preclinical evaluation.Clin Transl Gastroenterol. 2020; 11: e00164
Article info
Publication history
Footnotes
DISCLOSURE: The following authors disclosed financial relationships: C. Ma: Consultant for AVIR Pharma Inc and Alimentiv Inc; speaker for AVIR Pharma Inc. A. J. Bredenoord: Research support from Norgine, Nutricia, Thelial, SST, and Bayer; speaker and consultant for AstraZeneca, Medtronic, Laborie, Alimentiv, Celgene, DrFalkPharma, Arena, Esocap, Calypso, and Regeneron. E. S. Dellen: Research support from Adare/Ellodi, Allakos, AstraZeneca, Banner, Holoclara. GlaxoSmithKline, Meritage, Miraca, Nutricia, Celgene/Receptos/BMS, Regeneron, and Shire/Takeda; consultant for Abbott, Abbvie, Adare/ Ellodi, Aimmune, Allakos, Amgen, Arena, AstraZeneca, Avir, Biorasi, Calypso, Celgene/Receptos/BMS, Celldex, Eli Lilly, EsoCap, GlaxoSmithKline, Gossamer Bio, Landos, Morphic, Parexel/Calyx, Regeneron, Robarts/Alimentiv Inc, Salix, Sanofi, and Shire/Takeda. J. A. Alexander: Received research support from Regeneron, Adare, Arena, Celegene, and Ellode; consultant for Alimentiv; financial interest in Meritage Pharmacia. L. B Biedermann: Consultant and/or Falk Foundation, Vifor AG, Esocap AG, Sanofi-Aventis AG, and Calypso Biotech SA. M. Hogan, L. Guizzetti, J. Rémillard: Employee of Alimentiv Inc. G. Zou, L. M. Shackelton: Consultant for Alimentiv Inc. D. A. Katzka: Consultant for Takeda and Celgene. M. Chehade: Research support from Regeneron, Allakos, Shire, AstraZeneca, and Danone; consultant for Regeneron, Allakos, Adare, Shire/Takeda, AstraZeneca, Sanofi, Ellodi, Phathom, and Bristol Myers Squibb. G. W. Falk: Research support from Adare/Ellodi, Arena, Allakos, Celgene/Receptos/BMS, Lucid, Regeneron, and Shire/Takeda; consultant for Adare/Ellodi, Allakos, Arena, Celgene/Receptos/BMS, Lucid, Regeneron, Sanofi, and Shire/Takeda. G. T. Furuta: Research support from Holoclara and Arena; consultant for Takeda; cofounder of EnteroTrack. S. K. Gupta: Consultant for Abbott, Adare, Allakos, Celgene, Gossamer Bio, QOL, UpToDate, Medscape, and Viaskin; research support from Shire, Allakos, Adare, and National Institutes of Health U54 grant to the Consortium of Eosinophilic Gastrointestinal Disease Researchers. A. M. Schoepfer: Research support from Adare/Ellodi, AstraZeneca, Receptos/BMS, Dr Falk Pharma, Regeneron, and Vifor Pharma; consultant for Adare/Ellodi, Amgen, AstraZeneca, Celgene/Receptos/BMS, Dr Falk Pharma, GlaxoSmithKline, Gossamer Bio, Regeneron, Sanofi-Genzyme, and Vifor Pharma. S. Miehlke: Consultant for Dr Falk Pharma, EsoCap, Sanofi-Regeneron, and Celgene; Falk Foundation/Falk Foundation. F. J. Moawad: Consultant for Medtronic, Shire/Takeda, and Sanofi. K. Peterson: Research support from Adare/Ellodi, Allakos, AstraZeneca, Receptos/BMS, Regeneron, Shire/Takeda, and Chobani; consultant for Adare/Ellodi, Allakos, Alladapt, AstraZeneca, Celgene/Receptos/BMS, Regeneron, Sanofi, and Shire/Takeda. N. P. Gonsalves: Consultant for Allakos, Sanofi-Regeneron, Abbvie, Astra-Zeneca, and Nutriticia; royalties from Up-to-Date. A. Straumann: Consultant for Allakos, Astra-Zeneca, Calypso, EsoCap, Falk Pharma, Gossamer, Nutricia, Pfizer, Receptos-Celgene, Regeneron-Sanofi, Roche-Genentec, Shire, and Tillotts. J. B. Wechsler: Consultant for Allakos, Regeneron, and Sanofi/Genzyme. B. G. Feagan: Consultant for AbbVie, AdMIRx, AgomAB Therapeutics, Akebia, Alivio Therapeutics, Allakos, Amgen, Applied Molecular Transport Inc, Arena Pharma, Avir, Azora Therapeutics, Boehringer-Ingelheim, Boston Pharma, Celgene/BMS, Connect BioPharma, Cytoki, Disc Medicine, Everest Clinical Research Corp, Eli Lilly, Equillium, Ferring, Galapagos, Galen Atlantica, Genentech/Roche, Gilead, Glenmark, Gossamer Pharma, GSK, Hoffmann-LaRoche, Hot Spot Therapeutics, Index Pharma, ImmunExt, Imhotex, Intact Therapeutics, Janssen, Japan Tobacco Inc, Kaleido Biosciences, Leadiant, Millennium, MiroBio, Morphic Therapeutics, Mylan, OM Pharma, Origo BioPharma, Otsuka, Pandion Therapeutics, Pfizer, Prometheus Therapeutics and Diagnostics, Progenity, PTM Therapeutics, Q32 Bio, Rebiotix, RedHill, Biopharma, REDX, Sandoz, Sanofi, Seres Therapeutics, Surrozen Inc, Takeda, Teva, Thelium, Theravance, Tigenix, Tillotts, UCB Pharma, VHsquared Ltd, Viatris, Ysios, and Zealand Pharma; Speaker's Bureau for AbbVie, Janssen, and Takeda; Member, Scientific Advisory Board for AbbVie, Amgen, Boehringer-Ingelheim, Celgene/BMS Genentech/Roche, Janssen, Novartis, Origo BioPharma, Pfizer, Prometheus, Takeda, Tillotts Pharma, Teva, Progenity, Index, Ecor1Capital, Morphic, and GSK; Stock shareholder in Gossamer Pharma; Employee, Western University and Alimentiv Inc. V. Jairath: Consultant for AbbVie, Alimentiv Inc (formerly Robarts Clinical Trials), Arena Pharmaceuticals, Bristol Myers Squibb, Celltrion, Eli Lilly, Ferring, Fresenius Kabi, GlaxoSmithKline, Genetech, Gilead, Janssen, Merck, Mylan, Pendopharm, Pfizer, Roche, Sandoz, Takeda, and Topivert; speaker for Abbvie, Ferring, Janssen Pfizer Shire, and Takeda. I. Hurano: Research support from Adare/Ellodi, Allakos, AstraZeneca, Meritage, Receptos/BMS, Regeneron, and Shire/Takeda; consultant for Adare/Ellodi, Allakos, Amgen, Arena, AstraZeneca, Calypso, Celgene/Receptos/BMS, Eli Lilly, EsoCap, GlaxoSmithKline, Gossamer Bio, Parexel, Regeneron, Sanofi, and Shire/Takeda. All other authors disclosed no financial relationships.
